The role of APOBEC3B in chondrosarcoma

Jin,Zhe; Han,Ya-Xin; Han,Xiao-Rui

doi:10.3892/or.2014.3437

The role of APOBEC3B in chondrosarcoma

Authors:
- Zhe Jin
- Ya-Xin Han
- Xiao-Rui Han
View Affiliations

Affiliations: Department of Joint Surgery and Sports Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 22, 2014 https://doi.org/10.3892/or.2014.3437
Pages: 1867-1872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chondrosarcomas rank as the third most common type of bone tumors. In the present study, we demonstrated that expression of the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) was higher in cancer tissues when compared to that in normal tissues. In order to further investigate the effects of APOBEC3B expression, we knocked down APOBEC3B expression in chondrosarcoma cells. We found that the percentage of apoptotic cells was higher in the APOBEC3B-knockdown cells than the percentage in the untransfected cells. Furthermore, we found that the reduced antitumor activity of RUNX3 was caused by APOBEC3B. Finally, we demonstrated that caspase-3, -8 and -9 activity was significantly increased in the RUNX3-expressing cells with APOBEC3B knockdown. In summary, our results indicate that APOBEC3B knockdown may be a useful therapy to enhance apoptosis in chondrosarcoma.

View Figures

View References

1	Terek RM, Schwartz GK, Devaney K, et al: Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res. 16:585–590. 1998. View Article : Google Scholar : PubMed/NCBI
2	Hiraoka K, Zenmyo M, Komiya S, et al: Relationship of p21(waf1/cip1) and differentiation in chondrosarcoma cells. Virchows Arch. 440:285–290. 2002. View Article : Google Scholar : PubMed/NCBI
3	Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 69:6216–6222. 2009. View Article : Google Scholar : PubMed/NCBI
4	DeLaney TF, Liebsch NJ, Pedlow FX, et al: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 74:732–739. 2009. View Article : Google Scholar : PubMed/NCBI
5	Goila-Gaur R and Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 5:512008. View Article : Google Scholar : PubMed/NCBI
6	Heidmann T, Heidmann O and Nicolas JF: An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci USA. 85:2219–2223. 1988. View Article : Google Scholar
7	Macduff DA and Harris RS: Directed DNA deamination by AID/APOBEC3 in immunity. Curr Biol. 16:R186–R189. 2006. View Article : Google Scholar : PubMed/NCBI
8	Conticello SG: The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9:2292008. View Article : Google Scholar : PubMed/NCBI
9	Burns MB, Lackey L, Carpenter MA, et al: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494:366–370. 2013.PubMed/NCBI
10	Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL and Harris RS: Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274–4284. 2010.PubMed/NCBI
11	Burns MB, Temiz NA and Harris RS: Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 45:977–983. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kim DW, Kim KO, Shin MJ, et al: siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 8:282009. View Article : Google Scholar : PubMed/NCBI
13	Nishida K, Furumatsu T, Takada I, et al: Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ. Br J Cancer. 86:1303–1309. 2002.PubMed/NCBI
14	Jin Z, Han YX and Han XR: Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma. J Mol Histol. 44:645–652. 2013. View Article : Google Scholar : PubMed/NCBI
15	Xu R, Zhang X, Zhang W, Fang Y, Zheng S and Yu XF: Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology. 46:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
16	Chiu YL and Greene WC: The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 26:317–353. 2008. View Article : Google Scholar : PubMed/NCBI
17	Han YX and Liang DY: The role of the tumor suppressor RUNX3 in giant cell tumor of the bone. Int J Oncol. 40:673–678. 2011.PubMed/NCBI
18	Holmes RK, Koning FA, Bishop KN and Malim MH: APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem. 282:2587–2595. 2007. View Article : Google Scholar : PubMed/NCBI
19	Iwatani Y, Chan DS, Wang F, et al: Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096–7108. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mbisa JL, Barr R, Thomas JA, et al: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol. 81:7099–7110. 2007. View Article : Google Scholar
21	Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499:214–218. 2013. View Article : Google Scholar : PubMed/NCBI